Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study

Hung, Man-Hsin; Liu, Chia-Jen; Teng, Chih‐Ching; Hu, Yu-Wen; Yeh, Chiu-Mei; Chen, San‐Chi; Chien, Sheng-Hsuan; Hung, Yi‐Ping; Shen, Cheng Che; Chen, Tzeng Ji; Tzeng, Cheng‐Hwai; Liu, Chunyu

doi:10.1371/journal.pone.0148597

Cited by 26 publications

(54 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bilaterality occurred in 3.6% of the patients in the cohort within the present study, and was significantly associated with BRCA2 mutations and with the presence of NBPN. Male patients with BC also have an increased risk of NPBN, and the long survival times currently observed should be observed cautiously (42)(43)(44). A total of ~14% of the patients in the present study exhibited NBPN, and 2 with bilaterality and prostate carcinoma.…”

Section: Discussionmentioning

confidence: 56%

Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort

et al. 2019

View full text Add to dashboard Cite

Male breast cancer (BC) represents an individual subtype of BC, with therapeutic procedures based on female BC therapy results. The present study evaluated the parameters currently used for the characterization and therapy of male BC, and their association with disease-free (DFS) and overall survival (OS), aiming to obtain a comprehensive basis to improve the personalized care of male BC. A total of 196 patients from March 1970 to March 2018 (mean follow-up, 84.9 months) were profiled, using clinicopathological review, molecular assessment [BRCA1/2, DNA repair associated (BRCA1/2) status, immunohistochemistry, fluorescence in situ hybridization and DNA flow cytometry] and Cox regression statistical analysis. The median age of patients was 66.5 years. At presentation, 39.2% of patients with invasive carcinomas were in anatomic stage (AS) I. Patients exhibited primarily invasive carcinomas of no special type, histological grade 2, estrogen receptor α-(ERα) and progesterone receptor (PR)-positive, receptor tyrosine kinase erbB-2-negative, high Ki-67, Luminal B-like and aneuploid tumors. A total of 13 of the 44 (29.5%) BRCA-evaluated patients exhibited BRCA2 mutations, significantly associated with family history (FH), bilaterality, high Ki-67 expression, absence of PR and Luminal B-like tumors. Bilaterality was associated with the occurrence of non-breast primary neoplasms (NBPN). The 5 and 10-year DFS rates, excluding patients with distant metastasis, NBPN and in situ carcinomas (n=145) were 65.9 and 58.2%, respectively, and the 5 and 10-year OS rates were 77.5 and 59.2%, respectively. In the univariate analysis, Luminal B-like subtype, BRCA2 mutations, high Ki-67 expression, and AS II and III were significantly associated with shorter DFS and OS. In addition, age >70 years was associated with low OS. In the multivariate analysis, FH, AS II and III, and Luminal B-like subtypes were associated with poorer OS. In conclusion, the data from the present study emphasize the high incidence of BRCA2 mutation in male BC, and its association with FH, bilaterality, high Ki-67 expression, negative PR expression and Luminal B-like subtypes, and with shorter DFS and OS in univariate analysis.

show abstract

Section: Discussionmentioning

confidence: 56%

Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A Taiwan national survey of 578 BCM cases recently reported a significantly higher observed risk for SPC (SIR, 2.17; 95 % CI,1.70–2.73) after a median follow-up period of 3.85 years. 42 Additionally, data from 1926 BCM cases recruited from the California Cancer Registry from 1988 to 2003 also demonstrated a significantly higher risk of second cancer (SIR, 1.16; 95 % CI, 1.01–1.32). 25 Of 3409 BCM patients pooled from 13 cancer registries, 12.5 % experienced an SPC, with an overall excess risk of 34 %.…”

Section: Discussionmentioning

confidence: 97%

Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers

et al. 2018

View full text Add to dashboard Cite

Background. Low incidence of breast cancer in men (BCM) (<1 % of all breast cancers) has led to a paucity of outcome data. This study evaluated the impact of age on BCM outcomes. Methods. For this study, BCM patients treated between 2000 and 2011 were stratified by age (≤65 or >65 years). Kaplan-Meier methods were used to compare overall survival (OS) and breast cancer-specific survival (BCSS). Competing-risk methods analyzed time to second primary cancers (SPCs), with any-cause death treated as a competing risk. Results. The study identified 152 BCM patients with a median age of 64 years (range, 19–96 years). The median body mass index (BMI) was 28 kg/m2. Men age 65 years or younger (n = 78, 51 %) were more overweight/obese than men older than 65 years (n = 74, 49 %) (89 % vs 74 %, respectively; P = 0.008). Both groups had similar nodal metastases rates (P = 0.4), estrogen receptor positivity (P = 1), and human epidermal growth factor receptor 2 (HER2)neu overexpression (P = 0.6). Men 65 years of age or younger were more likely to receive chemotherapy (P = 0.002). The median follow-up period was 5.8 years (range, 0.1–14.4 years). The 5-year OS was 86 % (95 % confidence interval [CI], 80–93 %), whereas the 5-year BCSS was 95 % (95 % CI, 91–99 %). The BCM patients 65 years of age and younger had better OS (P = 0.003) but not BCSS (P = 0.8). The 5-year cumulative incidence of SPC was 8.4 % (95 % CI, 3.4–13.4 %). The prior SPC rate was higher for men older than 65 years (n = 20, 31 %) than for those age 65 years or younger (n = 7, 11 %) (P = 0.008). This did not account for differences in life years at risk. No difference was observed in SPC cumulative incidence stratified by age (P = 0.3). Conclusions. Men 65 years of age or younger received more chemotherapy and had improved OS, but not BCSS compared with men older than 65 years. For all BCM, SPC is a risk, and appropriate screening may be warranted.

show abstract

“…According to second primary cancer in our case, neuroendocrine tumor was happened in colon after one year and half from primary diagnosis of breast cancer which was a rare second primary malignancy (SPM) among female breast then bone and soft tissue cancers among female breast cancer patients [18]. In Dutch female breast cancer patients; the standardized incidence ratios (SIRs)…”

Section: Discussionmentioning

confidence: 80%

A Case Report of Two Primary Cancers, Breast Cancer with Adrenal Gland Metastatic and Second Primary Neuroendocrine Tumor in Colon, a Rare Case in Al-Bashir Hospital

Shamoun¹,

Shamout²

2018

CRCM

View full text Add to dashboard Cite

A 68 years old female, was diagnosed as a case of right breast cancer in 2013; grade II/III according to Bloom Richardson grading, Modify radical mastectomy (MRM) was done and the pathology report showed moderately differentiated invasive ductal carcinoma (IDC), stage T3N3M0. Immunohisrochemisty (IHC) findings revealed a tumor with Triple positive. Patient refused to treat by chemotherapy. Patient was given adjuvant trastuzumab (first dose 8 mg/kg, followed by 6 mg/kg every three weeks) for the period of one year (16) cycles after which she went on regular follow up. Exemestane tab for 5 years and radiotherapy (50 gray in 25 fractions) was applying on right breast. One year and half after diagnosed primary breast cancer, patient complained from severe diarrhea 8 times per day watery contents, vomiting and suffered from lower abdominal pain. PET scan for whole body in October 2014 was done; the results showed ascending colon is highly suspicious for malignancy and moderately hypermetabolic left adrenal mass. Subtotal colectomy surgery was done, the pathology report of biopsy revealed low grade malignant neuroendocrine neoplastic lesion stage of T3N1Mo. Physician prescribed octreotide acetate 20 mg I. M monthly due to neuroendocrine lesion. In January 2016, cancer recurrence in the same right breast, IHC revealed ER+, PR−, Her 2+, physician decided to change exemestane to fulvestrant 250 mg s. c for 6 cycles. Radiation therapy was applied 20 gray in 10 fractions on scar. In May 2016, CAP-CT scan result revealed two enlarged left axillary L.N and left soft tissue density adrenal mass (3.0 × 2.3).

show abstract

Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study

Cited by 26 publications

References 26 publications

Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort

Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort

Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers

A Case Report of Two Primary Cancers, Breast Cancer with Adrenal Gland Metastatic and Second Primary Neuroendocrine Tumor in Colon, a Rare Case in Al-Bashir Hospital

Contact Info

Product

Resources

About